MOBILion Systems is a pioneer in fast, efficient, high-resolution instrumentation for biomarker discovery, diagnostics and therapeutic development.
MOBILion Systems is focused on developing instruments that improve how we predict, diagnose and treat disease.
MOBILion Systems was founded in 2015 and is headquartered in Chadds Ford, Pennsylvania.
MOBILion is advancing separation science with the commercialization of High-Resolution Ion Mobility Mass Spectrometry (HRIMMS) products based on the SLIM (Structures for Lossless Ion Manipulation) platform technology, revealing what others leave unseen to better predict, diagnose and treat disease.
MOBILion's products provide greater instrument uptime, simplicity for broader use, and achieve currently difficult or impossible separations, streamlining characterization workflows with the speed, depth and efficiency our customers require to bring safer, more efficacious drugs to market faster and to make novel biomarker discoveries to diagnose diseases earlier.
MOBILion launched its first commercial HighResolution Ion Mobility (HRIM) product, MOBIE®, which addresses characterization challenges faced during biopharmaceutical drug development and quality monitoring.
MOBILion is backed by D1 Capital Partners, aMoon, Agilent Technologies, IP Group, Hostplus, Cultivation Capital, and others. The company raised $60M in Series C round on Jul 13, 2021. This brings MOBILion's total funding to $116.4M to date.